Page 197 | Certara

Publication

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

Twenty four hour ammonia profiles and correlates of drug effect were examined in a phase…

CertaraAugust 1, 2011

Knowledge Base

How Can PK/PD Analysis Add Value to Patient Care?

In May 2011, T.J. Smith and B.E. Hillner published an opinion piece in the New…

CertaraJuly 11, 2011

Knowledge Base

What is Curve Stripping?

The process of curve stripping is used in both compartmental and non-compartmental analysis. Each pharmacokinetic…

CertaraJuly 6, 2011

Publication

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

The purpose of this study was to develop a pharmacokinetic-pharmacodynamic disease progression (PK/PD/DIS) model to…

CertaraJuly 1, 2011

Publication

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Prospective pharmacokinetic study…

CertaraJuly 1, 2011

Publication

Simulation of Clinical Drug-drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

Rifampin and carbamazepine have been recommended in the U.S. Food and Drug Administration draft drug…

CertaraJuly 1, 2011

Publication

Metabolism of [D10]Phenanthrene to Tetraols in Smokers for Potential Lung Cancer Susceptibility Assessment: Comparison of Oral and Inhalation Routes of Administration

Polycyclic aromatic hydrocarbons (PAHs) are believed to be among the causative agents for lung cancer…

CertaraJuly 1, 2011

Publication

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P-450 3A4 (CYP3A4) from…

CertaraJune 14, 2011

Publication

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

A model-based strategy was used to inform the early clinical development of anacetrapib, a novel…

CertaraJune 1, 2011

Publication

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

Mechanistic PKPD models are now advocated not only by academic and industrial researchers, but also…

CertaraMay 11, 2011

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

How Can PK/PD Analysis Add Value to Patient Care?

What is Curve Stripping?

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Simulation of Clinical Drug-drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

Metabolism of [D10]Phenanthrene to Tetraols in Smokers for Potential Lung Cancer Susceptibility Assessment: Comparison of Oral and Inhalation Routes of Administration

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

Newsletter sign up

Quick links

Solutions

Contact